Kythera files $86M IPO to support fat-busting drug

After raising $108 million in venture cash, LA-based Kythera Biopharmaceuticals has filed for an IPO designed to contribute about $86 million. The IPO's success will hinge on the company's ability to generate some investor excitement over ATX-101, a late-stage fat-busting therapy intended to cure people of the double chin.

Kythera can make a good case that it's closing in on a product revenue stream. Bayer, which has ex-U.S. rights to the drug, has already completed a pair of positive late-stage studies on ATX-101. Kythera's Phase III trial, with 1,000 patients, got under way two months ago and should deliver data next year. And the biotech used its S-1 registration to tout its prospects in the $10 billion U.S. market for aesthetic treatments.

Kythera is banking on a simple but powerful human weakness: Vanity.

"Demand for facial injectable procedures is driven by the considerable importance of the face to overall appearance," the company says in the S-1. "We believe the growing variety and accessibility of non-surgical aesthetic procedures combined with increased social acceptance of aesthetic medicine in general have contributed to the adoption of these procedures by a broader patient demographic … [u]ndesirable submental fat, or double chin, remains an important yet unaddressed aesthetic target for injectable facial treatment." 

That market prospect has attracted an A-list group of venture backers. Versant Ventures, Arch Venture Partners, Prospect Venture Partners, JAFCO, Partner Funds management, INVUS Financial Advisors, BBT Capital Management/Apothecary Capital, Altitude Life Science Ventures, Foley Ventures and Latham and Watkins have all backed the company.

- here's the S-1
- read the press release
- get the story from Dow Jones

Suggested Articles

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.

Gilead presented studies at AASLD showing how noninvasive testing and machine learning could improve diagnostics and drug development for NASH.